Catherine Cherwin

Catherine Cherwin

Auto-generated profile, based on publicly available information

Catherine Cherwin

College of Nursing, University of Iowa, Iowa City, IA, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
KKKristine L. Kwekkeboom
Kristine L. Kwekkeboom
CCCatherine H. Cherwin
Catherine H. Cherwin
JLJun W. Lee
Jun W. Lee
BWBritt Wanta
Britt Wanta

1 December 2012 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
KKKristine L. Kwekkeboom
Kristine L. Kwekkeboom
KAKristen Abbott-Anderson
Kristen Abbott-Anderson
CCCatherine Cherwin
Catherine Cherwin
RRRachel Roiland
Rachel Roiland
RSRonald C. Serlin
Ronald C. Serlin
SWSandra E. Ward
Sandra E. Ward

26 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMeeta Yadav
Meeta Yadav
SASoham Ali
Soham Ali
RSRachel L. Shrode
Rachel L. Shrode
SSShailesh K. Shahi
Shailesh K. Shahi
SJSamantha N. Jensen
Samantha N. Jensen
AMAshutosh K Mangalam
Ashutosh K Mangalam
Trillions of microbes such as bacteria, fungi, and viruses exist in the healthy human gut microbiome. Although gut bacterial dysbiosis has been extensively studied in multiple sclerosis (MS), the significance of the fungal microbiome (mycobiome) is an understudied and neglected part of the intestinal microbiome in MS. The aim of this study was to characterize the gut mycobiome of patients with relapsing-remitting multiple sclerosis (RRMS), compare it to healthy controls, and examine its association with changes in the bacterial microbiome. We characterized and compared the mycobiome of 20 RRMS patients and 33 healthy controls (HC) using Internal Transcribed Spacer 2 (ITS2) and compared mycobiome interactions with the bacterial microbiome using 16S rRNA sequencing. Our results demonstrate an altered mycobiome in RRMS patients compared with HC. RRMS patients showed an increased abundance of Basidiomycota and decreased Ascomycota at the phylum level with an increased abundance of Candida and Epicoccum genera along with a decreased abundance of Saccharomyces compared to HC. We also observed an increased ITS2/16S ratio, altered fungal and bacterial associations, and altered fungal functional profiles in MS patients compared to HC. This study demonstrates that RRMS patients had a distinct mycobiome with associated changes in the bacterial microbiome compared to HC. There is an increased fungal to bacterial ratio as well as more diverse fungal-bacterial interactions in RRMS patients compared to HC. Our study is the first step towards future studies in delineating the mechanisms through which the fungal microbiome can influence MS disease.

28 February 2012 in Oncology Nursing Forum
Verified
Journal Article
Closed access
PDF file
CCCatherine H. Cherwin
Catherine H. Cherwin
To review how gastrointestinal (GI)symptoms are represented within symptom clusters in patients with cancer receiving chemotherapy. MedLINE, PsycINFO, and CINAHL. Forty-two symptom clusters containing a GI component emerged. Only four clusters were replicated in different samples; 38 were unique clusters. Thirteen different symptom measurement tools were used across the studies. Nineteen different GI symptoms were measured; however, many chemotherapy- or cancer-related GI symptoms known to be present in this population were missing or underrepresented. Twenty-one of the studies reviewed identified a symptom cluster that was primarily (50% or greater) composed of GI symptoms. GI symptoms are prevalent in symptom clusters, but those clusters often are inconsistent. One explanation for this finding may be that current symptom measurement tools do not fully address GI symptoms commonly experienced by patients receiving chemotherapy. Future research should focus on using a comprehensive symptom assessment tool in a homogenous sample of participants who are receiving chemotherapy. Improved measurement of GI symptoms will advance symptom cluster research, which could impact assessment of chemotherapy-related symptoms and development of interventions for symptom clusters.

6 July 2021 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
MMMegan Miller
Megan Miller
KKKristine Kwekkeboom
Kristine Kwekkeboom
CCCatherine Cherwin
Catherine Cherwin